ArticleMolecular oncology2016
Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.
Article in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast.Breast cancer research and treatment · 2025Article
- Surgery for Classic, Pleomorphic and Non-classic Lobular Carcinoma In Situ: Surgery Rate, Risk of Upstaging and Short-Term Follow-Up.Annals of surgical oncology · 2025Article
- Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.European journal of cancer (Oxford, England : 1990) · 2023Article
- Update on lobular lesions of the breast.Histopathology · 2023Review
- An update on intraductal and intralobular proliferative lesions of the breast.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Comparison of the Imaging Features of Lobular Carcinoma In Situ and Invasive Lobular Carcinoma of the Breast.Taehan Yongsang Uihakhoe chi · 2021Article
- Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors.Cancers · 2021Review
- Lobular carcinoma in situ: diagnostic criteria and molecular correlates.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications.Annals of diagnostic pathology · 2020Review
- Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer.NPJ breast cancer · 2020Article
- Lobular CarcinomasClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Lobular Carcinoma In Situ.Surgical pathology clinics · 2018Review
- SABCS 2017 pathology: from bench to bedside.Memo · 2018Review
- Precancer Atlas to Drive Precision Prevention Trials.Cancer research · 2017Article
- Developing Cures: Targeting Ontogenesis in Cancer.Trends in cancer · 2017Review
- PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.Breast cancer research : BCR · 2017Article
- The use of targeted genomic capture and massively parallel sequencing in diagnosis of Chinese Leukoencephalopathies.Scientific reports · 2016Article
- Leveraging premalignant biology for immune-based cancer prevention.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
purposeLobular carcinoma in situ (LCIS) has been proposed as a non-obligate precursor of invasive lobular carcinoma (ILC). Here we sought to define the repertoire of somatic genetic alterations in pure LCIS and in synchronous LCIS and ILC using targeted massively parallel sequencing.
methodsDNA samples extracted from microdissected LCIS, ILC and matched normal breast tissue or peripheral blood from 30 patients were subjected to massively parallel sequencing targeting all exons of 273 genes, including the genes most frequently mutated in breast cancer and DNA repair-related genes. Single nucleotide variants and insertions and deletions were identified using state-of-the-art bioinformatics approaches.
resultsThe constellation of somatic mutations found in LCIS (n = 34) and ILC (n = 21) were similar, with the most frequently mutated genes being CDH1 (56% and 66%, respectively), PIK3CA (41% and 52%, respectively) and CBFB (12% and 19%, respectively). Among 19 LCIS and ILC synchronous pairs, 14 (74%) had at least one identical mutation in common, including identical PIK3CA and CDH1 mutations. Paired analysis of independent foci of LCIS from 3 breasts revealed at least one common mutation in each of the 3 pairs (CDH1, PIK3CA, CBFB and PKHD1L1).
conclusionLCIS and ILC have a similar repertoire of somatic mutations, with PIK3CA and CDH1 being the most frequently mutated genes. The presence of identical mutations between LCIS-LCIS and LCIS-ILC pairs demonstrates that LCIS is a clonal neoplastic lesion, and provides additional evidence that at least some LCIS are non-obligate precursors of ILC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.